中文
| Catalogue |
|
|
| Recommend Products |
Adagene Inc.
United States, Manufacturer, Hits: 533, Updated:9/13/2022
United States |
Company Profile
-
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody?, SAFEbody?, and POWERbody? technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
Company News
- Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 1/21/2025
- Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzas... 10/10/2024
- Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-C... 9/18/2024
- Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) at ASC... 1/5/2024
- Adagene Appoints Cuong Do to Board of Directors and Audit Committee 11/22/2022
- Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116 10/12/2022
- Adagene Presents Interim Monotherapy Data at ESMO 2022 9/13/2022